Literature DB >> 19139820

Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction.

Francisco Coret1, Isabel Bosca, Loren Fratalia, Jaume Perez-Griera, Ana Pascual, Bonaventura Casanova.   

Abstract

Anti-Hu paraneoplastic syndromes are usually associated with an underlying neoplasia, although a few patients who are anti-Hu-positive never develop cancer after long-term follow-up. Tumour therapy remains the mainstay of therapeutic options, and early immune therapy in parallel is advisable. When no tumour is found, immunologically-based therapies are nowadays the only options. Recent studies have shown rituximab associated with the tumour therapy to be effective for some patients with anti-Hu paraneoplastic syndrome. We report a case of a patient with anti-Hu antibodies-associated sensory neuronopathy and gastric pseudo-obstruction without an underlying neoplasia four years after the first manifestation who has achieved sustained improvement for two years after treatment with rituximab. This case report supports the effectiveness of rituximab in these syndromes, even for cases where no underlying neoplasia is demonstrated. Further studies are warranted in order to confirm these preliminary data.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19139820     DOI: 10.1007/s11060-008-9787-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  13 in total

1.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.

Authors:  F Graus; F Keime-Guibert; R Reñe; B Benyahia; T Ribalta; C Ascaso; G Escaramis; J Y Delattre
Journal:  Brain       Date:  2001-06       Impact factor: 13.501

Review 2.  Paraneoplastic syndromes involving the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

3.  Hu-antibody-positive patients with or without cancer have similar clinical profiles.

Authors:  A Lladó; A F Carpentier; J Honnorat; P Sillevis-Smitt; A Twijnstra; Y Blanco; I K Hart; A Saiz; F Graus
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-08       Impact factor: 10.154

4.  HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal.

Authors:  A Szabo; J Dalmau; G Manley; M Rosenfeld; E Wong; J Henson; J B Posner; H M Furneaux
Journal:  Cell       Date:  1991-10-18       Impact factor: 41.582

5.  Successful treatment of paraneoplastic cerebellar degeneration with Rituximab.

Authors:  Marcello Esposito; P Penza; G Orefice; A Pagano; E Parente; A Abbadessa; V Bonavita
Journal:  J Neurooncol       Date:  2007-10-09       Impact factor: 4.130

6.  Spontaneous neurological improvement in anti-Hu associated encephalomyelitis.

Authors:  T Byrne; W P Mason; J B Posner; J Dalmau
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

7.  An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes.

Authors:  Setareh Shams'ili; Janet de Beukelaar; Jan Willem Gratama; Herbert Hooijkaas; Martin van den Bent; Mars van 't Veer; Peter Sillevis Smitt
Journal:  J Neurol       Date:  2006-01       Impact factor: 4.849

Review 8.  Advances in paraneoplastic neurological syndromes.

Authors:  Jérôme Honnorat; Stéphanie Cartalat-Carel
Journal:  Curr Opin Oncol       Date:  2004-11       Impact factor: 3.645

Review 9.  Paraneoplastic neurological syndromes: diagnosis and treatment.

Authors:  Francesc Graus; Josep Dalmau
Journal:  Curr Opin Neurol       Date:  2007-12       Impact factor: 5.710

10.  Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model.

Authors:  F Graus; I Illa; M Agusti; T Ribalta; F Cruz-Sanchez; C Juarez
Journal:  J Neurol Sci       Date:  1991-11       Impact factor: 3.181

View more
  13 in total

1.  A novel approach to paraneoplastic intestinal pseudo-obstruction.

Authors:  Ambuga Badari; Deborah Farolino; Eiad Nasser; Shahid Mehboob; David Crossland
Journal:  Support Care Cancer       Date:  2011-11-10       Impact factor: 3.603

2.  Paraneoplastic neurological syndromes: general treatment overview.

Authors:  Aurélien Viaccoz; Jérôme Honnorat
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

3.  Successful Treatment with Methylnaltrexone and IVIG for Paraneoplastic Syndrome-Associated Intestinal Pseudo-Obstruction.

Authors:  Cheng Zhang; Niravkumar J Patel; W Carl Jacobs; Sonal Ullman; Tyler M Berzin; Ram Chuttani; Anthony J Lembo; Jacqueline L Wolf
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-01

Review 4.  Enteric neuroplasticity and dysmotility in inflammatory disease: key players and possible therapeutic targets.

Authors:  Estelle T Spear; Gary M Mawe
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-10-11       Impact factor: 4.052

5.  Treatment of paraneoplastic neurologic disorders.

Authors:  John E Greenlee
Journal:  Curr Treat Options Neurol       Date:  2010-05       Impact factor: 3.598

6.  Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome.

Authors:  J Honnorat
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

7.  Limbic encephalitis and related cortical syndromes.

Authors:  Ignacio Rubio-Agusti; Miguel Salavert; Luis Bataller
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

Review 8.  Immunotherapy Prospects for Painful Small-fiber Sensory Neuropathies and Ganglionopathies.

Authors:  Anne Louise Oaklander
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

9.  Autoimmune Gastrointestinal Paralysis: Failure of Conventional Treatment without Immunomodulation.

Authors:  Craig Weinkauf; Sean McPhillips; Robert Krouse; Ira Levine
Journal:  Case Rep Surg       Date:  2014-09-18

Review 10.  Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review.

Authors:  Simone Rossi; Elena Merli; Roberto De Giorgio; Roberto D'Angelo; Rita Rinaldi; Gaia Deleonardi; Vincenzo Mastrangelo; Anna Simona Sasdelli; Alessandro Di Federico; Maria Guarino; Vincenzo Donadio; Loris Pironi; Francesco Gelsomino
Journal:  J Neurol       Date:  2021-05-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.